Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.3: prohibited at all times. Non-Specified. [1]
S4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulation
Apitegromab targets proforms of myostatin. The September 2026 US Isembyld label describes intravenous treatment of spinal muscular atrophy in adults and children aged two years or older who are already receiving SMN2-targeted treatment. A blanket description of apitegromab as only investigational is therefore outdated for the United States. [2]
- This is the checked US label, not a worldwide authorization or availability inventory.
Selected health warnings
The label warns about serious fractures and describes infections, vomiting, cough and other reactions in the studied SMA population. Animal findings raise fetal and reproductive concerns. These disease-specific data do not establish safety or a benefit-risk balance for healthy athletes. [2]
- The full label and clinician assessment remain necessary; listed risks are not exhaustive.
What remains uncertain
- No product-specific supplement-contamination pathway was established in this review; a medicine label does not establish contamination prevalence.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- ISEMBYLD apitegromab-mstn US prescribing information ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.